AbbVie needs new drugs as its mega-blockbuster Humira won’t bring in billions forever – and after the embarrassing withdrawal of an MS drug earlier this year it has managed to get a substan
Finland’s Forendo Pharma is beginning early-stage trials of a potential new treatment for endometriosis, joining a gang of biotechs vying to find new therapies for the debilitating conditio
AbbVie's elagolix has shown promise in a phase 2 trial in women with uterine fibroids, a second indication for the pipeline drug, which could become a major earner for the company.
